Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 17, Issue 1, 2015, Pages 94-97

  Sykes, A P ^a   O'Connor Semmes, R ^b   Dobbins, R ^b   Dorey, D J ^c   Lorimer, J D ^a   Walker, S ^d   Wilkison, W O ^d   Kler, L ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (Canada)

^d Islet Sciences Inc   (United States)

Author keywords

Remogliflozin etabonate; SGLT2; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; PLACEBO; REMOGLIFLOZIN ETABONATE; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; ANTIDIABETIC AGENT; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PRODRUG; PYRAZOLE DERIVATIVE; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DIABETIC PATIENT; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; URINARY TRACT INFECTION; WEIGHT CHANGE; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS; FOLLOW UP; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; INTENTION TO TREAT ANALYSIS; MIDDLE AGED; MULTICENTER STUDY; PATIENT DROPOUTS;

DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INTENTION TO TREAT ANALYSIS; MEMBRANE TRANSPORT MODULATORS; MIDDLE AGED; PATIENT DROPOUTS; PRODRUGS; PYRAZOLES; SODIUM-GLUCOSE TRANSPORTER 2; THIAZOLIDINEDIONES; WEIGHT LOSS;

EID: 84919478361     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12391     Document Type: Article

References (12)

1. Idris I, Donnelly R. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab 2009; 11: 79-88.
2. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 2012; 8: 495-502.
3. Abdul-Ghani MA, Norton L, DeFronzo RA. Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Curr Diab Rep 2012; 12: 230-238.
4. Dobbins RL, O'Connor-Semmes R, Kapur A et al. Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients. Diabetes Obes Metab 2012; 14: 15-22.
5. Rigalleau V, Lasseur C, Perlemoine C et al. Estimation of glomerular filtration rate in diabetic subjects Cockcroft formula or modification of diet in renal disease study equation? Diabetes Care 2005; 28: 838-843.
6. Tukey JW, Ciminera JL, Heyse JF. Testing the statistical certainty of a response to increasing doses of a drug. Biometrics 1985; 41: 295-301.
7. Smellie WS. Hypertriglyceridaemia in diabetes. BMJ 2006; 333: 1257-1260.
8. Kirk JK, Graves DE, Craven TE, Lipkin EW, Austion M, Margolis KL. Restricted-carbohydrate diets in patients with type 2 diabetes: a meta-analysis. J Am Diet Assoc 2008; 108: 91-100.
9. Bailey CJ, Iqbal N, T'joen C, List JF. Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab 2012; 14: 951-959.
10. Rosenstock J, Aggarwal N, Polidori D et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35: 1232-1238.
11. Sykes AP, Kemp GL, Dobbins R et al. Randomized efficacy and safety trial of once daily remogliflozin etabonate for the treatment of type 2 diabetes mellitus. Diabetes Obes Metab 2014; DOI: 10.1111/dom.12393.
12. Hussey EK, Kapur A, O'Connor-Semmes R et al. Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol 2013; 14: 25.